drugset / Trial / NCT02585869

Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

NCT02585869

Phase 2 Completed 161 enrolled NeuroBo Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of gemcabene on HDL-C, LDL-C, TG, and other lipid levels in patients with low HDL-C

Timeline

Start
1999-12
Primary completion
2001-06
Completion
2001-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcabene Small molecule 150 mg
Subject Gemcabene Small molecule 300 mg
Subject Gemcabene Small molecule 600 mg
Subject Gemcabene Small molecule 900 mg